Lilly Cuts Non-branded Lispro Prices By 40%; Positive Ph1 Data for New GLP-1RA Asset; Lifescan Presents Tu Salud Trial Data in Hispanic Population; EASD 2021 Key Press Releases (Sept 28)
On the second day of EASD 2021, three key press releases were observed from Lilly, Altimmune, and Lifescan. Below FENIX provides insights and context for the respective announcements.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.